Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) | |
US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(12 years from now) |
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9931305 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(11 months ago) | |
US9855221 | INDIVIOR INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(11 months ago) | |
US10285910 | INDIVIOR INC | Sublingual and buccal film compositions |
Oct, 2022
(3 months ago) | |
US8017150 | INDIVIOR INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(7 days from now) | |
US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month from now) | |
US11135216 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
US9687454 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
US8475832 | INDIVIOR INC | Sublingual and buccal film compositions |
Mar, 2030
(7 years from now) |
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(4 years from now) | |
US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(7 years from now) | |
US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) |
Market Authorisation Date: 03 July, 2013
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence
Dosage: TABLET;SUBLINGUAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic